51
|
Garvin AJ, Khalaf AHA, Rettino A, Xicluna J, Butler L, Morris JR, Heery DM, Clarke NM. GSK3β-SCFFBXW7α mediated phosphorylation and ubiquitination of IRF1 are required for its transcription-dependent turnover. Nucleic Acids Res 2019; 47:4476-4494. [PMID: 30854564 PMCID: PMC6511875 DOI: 10.1093/nar/gkz163] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2018] [Revised: 02/19/2019] [Accepted: 03/07/2019] [Indexed: 01/03/2023] Open
Abstract
IRF1 (Interferon Regulatory Factor-1) is the prototype of the IRF family of DNA binding transcription factors. IRF1 protein expression is regulated by transient up-regulation in response to external stimuli followed by rapid degradation via the ubiquitin-proteasome system. Here we report that DNA bound IRF1 turnover is promoted by GSK3β (Glycogen Synthase Kinase 3β) via phosphorylation of the T181 residue which generates a phosphodegron for the SCF (Skp-Cul-Fbox) ubiquitin E3-ligase receptor protein Fbxw7α (F-box/WD40 7). This regulated turnover is essential for IRF1 activity, as mutation of T181 results in an improperly stabilized protein that accumulates at target promoters but fails to induce RNA-Pol-II elongation and subsequent transcription of target genes. Consequently, the anti-proliferative activity of IRF1 is lost in cell lines expressing T181A mutant. Further, cell lines with dysfunctional Fbxw7 are less sensitive to IRF1 overexpression, suggesting an important co-activator function for this ligase complex. As T181 phosphorylation requires both DNA binding and RNA-Pol-II elongation, we propose that this event acts to clear ‘spent’ molecules of IRF1 from transcriptionally engaged target promoters.
Collapse
Affiliation(s)
- Alexander J Garvin
- School of Pharmacy, University of Nottingham, University Park, Nottingham, UK.,Institute of Cancer & Genomic Sciences, University of Birmingham, Edgbaston, UK
| | - Ahmed H A Khalaf
- School of Pharmacy, University of Nottingham, University Park, Nottingham, UK
| | - Alessandro Rettino
- School of Pharmacy, University of Nottingham, University Park, Nottingham, UK
| | - Jerome Xicluna
- School of Pharmacy, University of Nottingham, University Park, Nottingham, UK
| | - Laura Butler
- Institute of Cancer & Genomic Sciences, University of Birmingham, Edgbaston, UK
| | - Joanna R Morris
- Institute of Cancer & Genomic Sciences, University of Birmingham, Edgbaston, UK
| | - David M Heery
- School of Pharmacy, University of Nottingham, University Park, Nottingham, UK
| | - Nicole M Clarke
- School of Pharmacy, University of Nottingham, University Park, Nottingham, UK
| |
Collapse
|
52
|
Feng DD, Cao Q, Zhang DQ, Wu XL, Yang CX, Chen YF, Yu T, Qi HX, Zhou GP. Transcription factor E2F1 positively regulates interferon regulatory factor 5 expression in non-small cell lung cancer. Onco Targets Ther 2019; 12:6907-6915. [PMID: 31692554 PMCID: PMC6711570 DOI: 10.2147/ott.s215701] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2019] [Accepted: 08/02/2019] [Indexed: 12/24/2022] Open
Abstract
Purpose Lung cancer is the most common malignant tumor in the world, and its incidence and mortality are very high. This study focuses on the mechanism of non-small cell lung cancer to find new therapeutic targets. Methods We used RT-PCR and Western blot to verify the linear relationship between E2F1 and IRF5 in normal lung tissue and lung cancer tissues. Secondly, we used overexpression and knock down E2F1 in cell lines to detect the expression of IRF5. The prime enzyme reporter plasmid verified that E2F1 binds to the core promoter region of IRF5; finally, CHIP experiments demonstrated that E2F1 binds directly to IRF5. Results We verified that E2F1 and IRF5 are decreased in patient tissues, and there is a strong linear relationship between E2F1 and IRF5. Secondly, we used overexpression of E2F1 or E2F1 siRNA transfected into HCC827 cells and found that E2F1 positively regulates the activity of the IRF5 promoter and the mRNA level of IRF5. Finally, the results of a chromatin immunoprecipitation assay demonstrated that E2F1 bound to the promoter region of IRF5 in vitro. These results suggested that the E2F1 transcription factor is the primary determinant for activating the basal transcription of the IRF5. Conclusion The transcription factor E2F1 positively regulates IRF5 in non-small cell lung cancer.
Collapse
Affiliation(s)
- Dan-Dan Feng
- Department of Pediatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China
| | - Qian Cao
- Department of Pediatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China
| | - Dao-Qi Zhang
- Department of Pediatrics, Children's Hospital of Soochow University, Soochow University, Suzhou, Jiangsu Province 215025, China
| | - Xiao-Lu Wu
- Department of Pediatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China
| | - Cai-Xia Yang
- Department of Pediatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China
| | - Yu-Fei Chen
- Department of Pediatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China
| | - Tang Yu
- Department of Chest Surgery, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China
| | - Hai-Xiao Qi
- Department of Pediatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China
| | - Guo-Ping Zhou
- Department of Pediatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China
| |
Collapse
|
53
|
Interferon regulatory factor-1 reverses chemoresistance by downregulating the expression of P-glycoprotein in gastric cancer. Cancer Lett 2019; 457:28-39. [DOI: 10.1016/j.canlet.2019.05.006] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2019] [Revised: 03/31/2019] [Accepted: 05/06/2019] [Indexed: 02/08/2023]
|
54
|
de Sousa JC, da Nóbrega Ito M, Costa MB, Farias IR, de Paula Borges D, de Oliveira RT, Fukutani KF, Thomé CH, da Silva Martinelli CM, Myajima F, Vidal DO, Magalhães SMM, Figueiredo-Pontes LL, Pinheiro RF. Dysregulation of interferon regulatory genes reinforces the concept of chronic immune response in myelodysplastic syndrome pathogenesis. Hematol Oncol 2019; 37:523-526. [PMID: 30920666 DOI: 10.1002/hon.2608] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Revised: 03/21/2019] [Accepted: 03/23/2019] [Indexed: 12/31/2022]
Affiliation(s)
- Juliana Cordeiro de Sousa
- Cytogenomic Laboratory, Postgraduate Medical Science, University Federal of Ceará, Fortaleza, Brazil
| | - Mayumi da Nóbrega Ito
- Cytogenomic Laboratory, Postgraduate Medical Science, University Federal of Ceará, Fortaleza, Brazil.,Center for Drug Research and Development, Federal University of Ceará (NPDM, UFC), Fortaleza, Brazil
| | - Marilia Braga Costa
- Cytogenomic Laboratory, Postgraduate Medical Science, University Federal of Ceará, Fortaleza, Brazil.,Center for Drug Research and Development, Federal University of Ceará (NPDM, UFC), Fortaleza, Brazil
| | - Izabelle Rocha Farias
- Cytogenomic Laboratory, Postgraduate Medical Science, University Federal of Ceará, Fortaleza, Brazil.,Center for Drug Research and Development, Federal University of Ceará (NPDM, UFC), Fortaleza, Brazil
| | - Daniela de Paula Borges
- Cytogenomic Laboratory, Postgraduate Medical Science, University Federal of Ceará, Fortaleza, Brazil.,Center for Drug Research and Development, Federal University of Ceará (NPDM, UFC), Fortaleza, Brazil
| | - Roberta Taiane de Oliveira
- Cytogenomic Laboratory, Postgraduate Medical Science, University Federal of Ceará, Fortaleza, Brazil.,Center for Drug Research and Development, Federal University of Ceará (NPDM, UFC), Fortaleza, Brazil
| | - Kiyoshi Ferreira Fukutani
- Department of Biochemistry, Immunology, and Cell Biology, the Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
| | - Carolina Hassibe Thomé
- Hematology Division, Ribeirao Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
| | | | - Fabio Myajima
- Center for Drug Research and Development, Federal University of Ceará (NPDM, UFC), Fortaleza, Brazil.,Fundação Oswaldo Cruz, Ceará Fiocruz, Brazil
| | - Daniel Onofre Vidal
- Molecular Oncology Research Center, Barretos Cancer Hospital, São Paulo, Brazil
| | | | | | - Ronald Feitosa Pinheiro
- Cytogenomic Laboratory, Postgraduate Medical Science, University Federal of Ceará, Fortaleza, Brazil.,Center for Drug Research and Development, Federal University of Ceará (NPDM, UFC), Fortaleza, Brazil
| |
Collapse
|
55
|
Abstract
Three decades of research in hematopoietic stem cell transplantation and HIV/AIDS fields have shaped a picture of immune restoration disorders. This manuscript overviews the molecular biology of interferon networks, the molecular pathogenesis of immune reconstitution inflammatory syndrome, and post-hematopoietic stem cell transplantation immune restoration disorders (IRD). It also summarizes the effects of thymic involution on T cell diversity, and the results of the assessment of diagnostic biomarkers of IRD, and tested targeted immunomodulatory treatments.
Collapse
Affiliation(s)
- Hesham Mohei
- Department of Medicine, University of Minnesota, Minneapolis, USA
| | - Usha Kellampalli
- Department of Medicine, University of Minnesota, Minneapolis, USA
| | | |
Collapse
|
56
|
Fochi S, Bergamo E, Serena M, Mutascio S, Journo C, Mahieux R, Ciminale V, Bertazzoni U, Zipeto D, Romanelli MG. TRAF3 Is Required for NF-κB Pathway Activation Mediated by HTLV Tax Proteins. Front Microbiol 2019; 10:1302. [PMID: 31244811 PMCID: PMC6581700 DOI: 10.3389/fmicb.2019.01302] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2019] [Accepted: 05/24/2019] [Indexed: 01/23/2023] Open
Abstract
Human T-cell leukemia viruses type 1 (HTLV-1) and type 2 (HTLV-2) share a common genome organization and expression strategy but have distinct pathological properties. HTLV-1 is the etiological agent of Adult T-cell Leukemia (ATL) and of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP), whereas HTLV-2 does not cause hematological disorders and is only sporadically associated with cases of subacute myelopathy. Both HTLV genomes encode two regulatory proteins that play a pivotal role in pathogenesis: the transactivating Tax-1 and Tax-2 proteins and the antisense proteins HBZ and APH-2, respectively. We recently reported that Tax-1 and Tax-2 form complexes with the TNF-receptor associated factor 3, TRAF3, a negative regulator of the non-canonical NF-κB pathway. The NF-κB pathway is constitutively activated by the Tax proteins, whereas it is inhibited by HBZ and APH-2. The antagonistic effects of Tax and antisense proteins on NF-κB activation have not yet been fully clarified. Here, we investigated the effect of TRAF3 interaction with HTLV regulatory proteins and in particular its consequence on the subcellular distribution of the effector p65/RelA protein. We demonstrated that Tax-1 and Tax-2 efficiency on NF-κB activation is impaired in TRAF3 deficient cells obtained by CRISPR/Cas9 editing. We also found that APH-2 is more effective than HBZ in preventing Tax-dependent NF-κB activation. We further observed that TRAF3 co-localizes with Tax-2 and APH-2 in cytoplasmic complexes together with NF-κB essential modulator NEMO and TAB2, differently from HBZ and TRAF3. These results contribute to untangle the mechanism of NF-κB inhibition by HBZ and APH-2, highlighting the different role of the HTLV-1 and HTLV-2 regulatory proteins in the NF-κB activation.
Collapse
Affiliation(s)
- Stefania Fochi
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Verona, Italy
| | - Elisa Bergamo
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Verona, Italy
| | - Michela Serena
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Verona, Italy
| | - Simona Mutascio
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Verona, Italy
| | - Chloé Journo
- Retroviral Oncogenesis Laboratory, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111 - Université Claude Bernard Lyon 1, CNRS, Equipe Labellisée "Fondation pour la Recherche Médicale", UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, Lyon, France
| | - Renaud Mahieux
- Retroviral Oncogenesis Laboratory, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111 - Université Claude Bernard Lyon 1, CNRS, Equipe Labellisée "Fondation pour la Recherche Médicale", UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, Lyon, France
| | - Vincenzo Ciminale
- Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.,Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Umberto Bertazzoni
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Verona, Italy
| | - Donato Zipeto
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Verona, Italy
| | - Maria Grazia Romanelli
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Verona, Italy
| |
Collapse
|
57
|
Compagnone M, Cifaldi L, Fruci D. Regulation of ERAP1 and ERAP2 genes and their disfunction in human cancer. Hum Immunol 2019; 80:318-324. [PMID: 30825518 DOI: 10.1016/j.humimm.2019.02.014] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2018] [Revised: 02/01/2019] [Accepted: 02/26/2019] [Indexed: 12/18/2022]
Abstract
The endoplasmic reticulum (ER) aminopeptidases ERAP1 and ERAP2 are two multifunctional enzymes playing an important role in the biological processes requiring trimming of substrates, including the generation of major histocompatibility complex (MHC) class I binding peptides. In the absence of ERAP enzymes, the cells exhibit a different pool of peptides on their surface which can promote both NK and CD8+ T cell-mediated immune responses. The expression of ERAP1 and ERAP2 is frequently altered in tumors, as compared to their normal counterparts, but how this affects tumor growth and anti-tumor immune responses has been little investigated. This review will provide an overview of current knowledge on transcriptional and post-transcriptional regulations of ERAP enzymes, and will discuss the contribution of recent studies to our understanding of ERAP1 and ERAP2 role in cancer immunity.
Collapse
Affiliation(s)
- Mirco Compagnone
- Paediatric Haematology/Oncology Department, Ospedale Pediatrico Bambino Gesù, 00146 Rome, Italy
| | - Loredana Cifaldi
- Academic Department of Pediatrics (DPUO), Ospedale Pediatrico Bambino Gesù, 00146 Rome, Italy
| | - Doriana Fruci
- Paediatric Haematology/Oncology Department, Ospedale Pediatrico Bambino Gesù, 00146 Rome, Italy.
| |
Collapse
|
58
|
Intratype variants of the E2 protein from human papillomavirus type 18 induce different gene expression profiles associated with apoptosis and cell proliferation. Arch Virol 2019; 164:1815-1827. [DOI: 10.1007/s00705-018-04124-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2018] [Accepted: 11/21/2018] [Indexed: 11/30/2022]
|
59
|
Jin D, Guo J, Wang D, Wu Y, Wang X, Gao Y, Shao C, Xu X, Tan S. The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC. EBioMedicine 2018; 37:188-204. [PMID: 30389502 PMCID: PMC6284514 DOI: 10.1016/j.ebiom.2018.10.044] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Revised: 10/12/2018] [Accepted: 10/15/2018] [Indexed: 02/06/2023] Open
Abstract
Background Activation of the oncogene YAP has been shown to be related to lung cancer progression and associates with poor prognosis and metastasis. Metformin is a drug commonly used in the treatment of diabetes and with anticancer activity. However, the mechanism through which metformin inhibits tumorigenesis via YAP is poorly understood. Methods The mRNA and protein expressions were analyzed by RT-PCR and western blot. The cellular proliferation was detected by CCK8 and MTT. The cell migration and invasion growth were analyzed by wound healing assay and transwell assay. The activities of promoter were analyzed by luciferase reporter assay. Chromatin immunoprecipitation detected the combining ability of IRF-1 and 5′UTR-YAP. Findings Our immunohistochemistry staining and RT-PCR assays showed that the expression of YAP was higher in lung carcinoma samples. Interestingly, metformin was able to downregulate YAP mRNA and protein expression in lung cancer cells. Mechanistically, we found that metformin depressed YAP promoter by competing with the binding of the transcription factor IRF-1 in lung cancer cells. Moreover, combination of metformin and verteporfin synergistically inhibits cell proliferation, promotes apoptosis and suppresses cell migration/invasion by downregulating YAP, therefore reduces the side effects caused by their single use and improve the quality of life for patients with lung cancer. Interpretation we concluded that metformin depresses YAP promoter by interfering with the binding of the transcription factor IRF-1. Importantly, verteporfin sensitizes metformin-induced the depression of YAP and inhibition of cell growth and invasion in lung cancer cells. Fund This work was supported by National Natural Science Foundation of China (No.31801085), the Science and Technology Development Foundation of Yantai (2015ZH082), Natural Science Foundation of Shandong Province (ZR2018QH004, ZR2016HB55, ZR2017PH067 and ZR2017MH125), and Research Foundation of Binzhou Medical University (BY2015KYQD29 and BY2015KJ14).
Collapse
Affiliation(s)
- Dan Jin
- Department of Pain, Binzhou Medical University Hospital, Binzhou 256603, PR China
| | - Jiwei Guo
- Cancer research institute, Binzhou Medical University Hospital, Binzhou 256603, PR China.
| | - Deqiang Wang
- Department of Pain, Binzhou Medical University Hospital, Binzhou 256603, PR China
| | - Yan Wu
- Cancer research institute, Binzhou Medical University Hospital, Binzhou 256603, PR China
| | - Xiaohong Wang
- Department of Thyroid and Breast Surgery, Binzhou Medical University Hospital, Binzhou 256603, PR China
| | - Yong Gao
- Department of Pain, Binzhou Medical University Hospital, Binzhou 256603, PR China
| | - Cuijie Shao
- Department of Pain, Binzhou Medical University Hospital, Binzhou 256603, PR China
| | - Xin Xu
- Department of Pain, Binzhou Medical University Hospital, Binzhou 256603, PR China
| | - Shuying Tan
- Department of Pain, Binzhou Medical University Hospital, Binzhou 256603, PR China
| |
Collapse
|